---
title: "Lysergide (DT120) in Generalized anxiety disorder: References"
description: "Reference list for the formulary evidence report on Lysergide (DT120, MM120) in Generalized anxiety disorder. 199 cited documents."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: References

<a id="references"></a>

## 5 References

1. [American Psychological Association Mental and Behavioral Health Registry measures page (2026)](https://www.apaservices.org/practice/reimbursement/health-registry/measures)
2. [Archer et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11627142/)
3. [Arikci et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12355019/)
4. [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)
5. [Bandelow (2006)](https://pubmed.ncbi.nlm.nih.gov/17008827/)
6. [Bandelow et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25932596/)
7. [Bandelow et al. (2023)](https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2086295)
8. [Batelaan et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26932485/)
9. [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)
10. [Becker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9926053/)
11. [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)
12. [Bentley et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771521/)
13. [Berger et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266199/)
14. [BrainFutures CPT and HCPCS coding guide (2023)](https://www.brainfutures.org/wp-content/uploads/2023/09/A-Guide-to-CPT-and-HCPCS-Codes-for-Psychedelic-Assisted-Therapy_Charts.pdf)
15. [Bruce et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3272761/)
16. [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf)
17. [Carhart-Harris and Nutt (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5606297/)
18. [Carl et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063818/)
19. [Chessick et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8915394/)
20. [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)
21. [ClinicalTrials.gov NCT00920387 results](https://clinicaltrials.gov/study/NCT00920387?tab=results)
22. [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579)
23. [ClinicalTrials.gov NCT05407064](https://clinicaltrials.gov/study/NCT05407064)
24. [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results)
25. [ClinicalTrials.gov NCT05964647](https://clinicaltrials.gov/study/NCT05964647)
26. [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)
27. [ClinicalTrials.gov NCT06809595](https://clinicaltrials.gov/study/NCT06809595)
28. [CMS CY 2020 Physician Fee Schedule final rule (2019)](https://www.federalregister.gov/documents/2019/11/15/2019-24086/medicare-program-cy-2020-revisions-to-payment-policies-under-the-physician-fee-schedule-and-other-changes-to-part)
29. [CMS Use of High-Risk Medications in Older Adults eCQM flow (2025)](https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS156-v14.0.000-eCQM-Flow.pdf)
30. [Costello et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6661660/)
31. [COVID-19 Mental Disorders Collaborators (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500697/)
32. [CTIS 2024-513572-17-00](https://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00)
33. [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)
34. [Cuijpers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24487344/)
35. [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf)
36. [de Vries et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6667912/)
37. [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)
38. [Definium Therapeutics executive order statement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/221/definium-therapeutics-applauds-white-house-executive-order-to-accelerate-mental-health-innovation-and-expand-access-to-psychedelic-medical-treatments)
39. [Definium Therapeutics expanded access policy (2025)](https://definiumtx.com/expanded-access-policy/)
40. [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)
41. [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)
42. [Definium Therapeutics Form 8-K name change (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526009854/mnmd-20260109.htm)
43. [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)
44. [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf)
45. [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)
46. [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)
47. [Definium Therapeutics January 2026 corporate presentation (2026)](https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001193125-26-009854/0001193125-26-009854.pdf)
48. [Definium Therapeutics LSD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/08/DFTX-FactSheet-LSD-080526.pdf)
49. [Definium Therapeutics May 2026 corporate presentation (2026)](https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001193125-26-229657/dftx-ex99_1.htm)
50. [Definium Therapeutics MDD Breakthrough Therapy designation announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/247/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally-disintegrating-tablet-odt-in-major-depressive-disorder-mdd-following-positive-phase-3-results)
51. [Definium Therapeutics NEI Fall Congress announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/257/definium-therapeutics-presents-topline-phase-3-data-for-dt120-odt-in-generalized-anxiety-disorder-and-major-depressive-disorder-at-2026-nei-fall-congress)
52. [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)
53. [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)
54. [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)
55. [Definium Therapeutics second quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/242/definium-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights)
56. [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)
57. [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)
58. [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)
59. [Definium Therapeutics ticker change announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/208/definium-therapeutics-common-shares-to-trade-under-new-nasdaq-ticker-symbol-dftx-effective-january-15-2026)
60. [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf)
61. [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)
62. [Definium Therapeutics Wired for Worry announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/238/definium-therapeutics-launches-wired-for-worry-a-health-care-provider-initiative-to-advance-the-understanding-of-generalized-anxiety-disorder-gad-patient-impact-and-neurobiology)
63. [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)
64. [Dieleman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7054840/)
65. [Dolder et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5591798/)
66. [Domschke et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10785995/)
67. [Duong et al. (2024a)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/137867)
68. [Duong et al. (2024b)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/138043)
69. [Duong et al. (2024c)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3900/137986)
70. [Duong et al. (2024d)](https://d1io3yog0oux5.cloudfront.net/_1e86c849bdc3b52ea5177f8157ee1069/mindmed/db/2265/21481/pdf/MNMD+AMCP+Nexus+2024+Poster.pdf)
71. [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843)
72. [Duong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41519172/)
73. [eCFR 21 CFR 1308.11](https://www.ecfr.gov/current/title-21/chapter-II/part-1308/subject-group-ECFR3cfa0fa9ca4d0b5/section-1308.11)
74. [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf)
75. [EMA Lyrica product information (2026)](https://www.ema.europa.eu/en/documents/product-information/lyrica-epar-product-information_en.pdf)
76. [Etkin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12553334/)
77. [Ettman et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39123097/)
78. [Executive Office of the President (2026)](https://www.federalregister.gov/documents/2026/04/22/2026-07907/accelerating-medical-treatments-for-serious-mental-illness)
79. [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class)
80. [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)
81. [Ferries et al. (2025)](https://www.hmpgloballearningnetwork.com/node/371502)
82. [Ferries et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019603/)
83. [Fonzo and Etkin (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573561/)
84. [Frokjaer et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17884017/)
85. [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)
86. [Gasser et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25389218/)
87. [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/)
88. [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)
89. [Gonçalves and Byrne (2012)](https://pubmed.ncbi.nlm.nih.gov/21907538/)
90. [Goodwin et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7441973/)
91. [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)
92. [Grant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2766434/)
93. [Greenberg et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10453795/)
94. [Guaiana et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13139711/)
95. [Hamilton (1959)](https://pubmed.ncbi.nlm.nih.gov/13638508/)
96. [Harrewijn et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8486763/)
97. [Healthmonix 2026 Mental and Behavioral Health Registry announcement (2026)](https://healthmonix.com/2026/02/05/2026-mental-and-behavioral-health-registry-mbhr/)
98. [Hettema et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11578982/)
99. [Hidalgo et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17984162/)
100. [Hoffman et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17146763/)
101. [Holze et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6595343/)
102. [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)
103. [Holze et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166834/)
104. [Holze et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9018810/)
105. [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/)
106. [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)
107. [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/)
108. [HRA Phase 1 PK study of MM-120 in healthy volunteers (2023)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-in-healthy-volunteers/)
109. [HRA Phase 1 PK study of MM-120 under fed and fasted conditions (2024)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-under-fed-and-fasted-conditions-in-healthy-volunteers/)
110. [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)
111. [ISRCTN ISRCTN11052603](https://www.isrctn.com/ISRCTN11052603)
112. [ISRCTN ISRCTN15997848](https://www.isrctn.com/ISRCTN15997848)
113. [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)
114. [Janssen SPRAVATO prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf)
115. [Kanwar et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23408488/)
116. [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)
117. [Kessler et al. (2005a)](https://pubmed.ncbi.nlm.nih.gov/15939837/)
118. [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/)
119. [Kessler et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2745899/)
120. [Kessler et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4005415/)
121. [Konnopka and König (2020)](https://pubmed.ncbi.nlm.nih.gov/31646432/)
122. [Kroenke et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17339617/)
123. [Levey et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7869502/)
124. [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)
125. [Louie (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/healthcare-resource-utilization-in-patients-with-co-occurring-generalized-anxiety-disorder-and-major-depressive-disorder-a-real-world-claims-analysis)
126. [Luethi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30981875/)
127. [Lyrica prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021446s046,022488s022lbl.pdf)
128. [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)
129. [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/)
130. [Martens et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20603456/)
131. [Mavranezouli et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23512146/)
132. [Meier et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5082973/)
133. [MindMed APA presentation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/144/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york)
134. [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)
135. [MindMed Catalent license announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/121/mindmed-announces-exclusive-license-agreement-with-catalent-for-its-patented-zydis-fast-dissolve-technology-for-use-with-mm-120)
136. [MindMed corporate presentation (2025)](https://definiumtx.com/wp-content/uploads/2025/11/MindMed-Corporate-Presentation_November-2025.pdf)
137. [MindMed end-of-phase 2 meeting announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/149/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad)
138. [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)
139. [MindMed IND clearance announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/54/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder)
140. [MindMed IND clinical hold announcement (2021)](https://ir.definiumtx.com/news-events/press-releases/detail/60/mindmed-provides-status-update-on-ind-for-phase-2b-trial-of-lsd-for-the-treatment-of-generalized-anxiety-disorder)
141. [MindMed Innovation Passport announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/167/mindmed-awarded-innovation-passport-designation-by-the-united-kingdom-uk-innovative-licensing-and-access-pathway-ilap-steering-group-for-mm120-orally-disintegrating-tablet-odt-for-generalized-anxiety-disorder-gad)
142. [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)
143. [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders)
144. [MindMed MMED008 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/Prot_000.pdf)
145. [MindMed MMED008 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/64/NCT05407064/SAP_001.pdf)
146. [MindMed ODT patent announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/152/mindmed-announces-issuance-of-new-patent-for-mm120-orally-disintegrating-tablet-odt)
147. [MindMed Panorama first patient dosed announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/171/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder)
148. [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)
149. [MindMed Phase 2b enrollment completion announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/125/mindmed-completes-enrollment-of-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder-gad)
150. [MindMed Phase 2b first patient dosed announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/29/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)
151. [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder)
152. [MindMed suicidal ideation study announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/194/new-mindmed-retrospective-study-presented-at-psych-congress-2025-reveals-high-rates-of-suicidal-ideation-si-in-adults-with-generalized-anxiety-disorder-gad)
153. [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)
154. [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)
155. [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)
156. [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf)
157. [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)
158. [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)
159. [NCQA Use of High-Risk Medications in Older Adults measure description](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/use-of-high-risk-medications-in-older-adults-dae/)
160. [Newman et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4964851/)
161. [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)
162. [Olatunji et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17343963/)
163. [Patriquin and Mathew (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/)
164. [Paxil prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020031s081lbl.pdf)
165. [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)
166. [Plummer et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26719105/)
167. [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)
168. [Purves et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7237282/)
169. [Revicki et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22154706/)
170. [Ringeisen et al. (2023)](https://www.rti.org/publication/mental-and-substance-use-disorders-prevalence-study/fulltext.pdf)
171. [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)
172. [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)
173. [Roest et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20620715/)
174. [Ross and Soeteman (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920520/)
175. [Roy-Byrne et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928714/)
176. [RTI International (2023)](https://www.rti.org/publication/mental-substance-use-disorders-prevalence-study-findings-report)
177. [Rubio and Lopez-Ibor (2007)](https://pubmed.ncbi.nlm.nih.gov/17430415/)
178. [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)
179. [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)
180. [Shirneshan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24135257/)
181. [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)
182. [Soares (2025)](https://pubmed.ncbi.nlm.nih.gov/40906492/)
183. [Solmi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8960395/)
184. [Spitzer et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16717171/)
185. [Stein and Sareen (2015)](https://pubmed.ncbi.nlm.nih.gov/26580998/)
186. [Straumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10584820/)
187. [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)
188. [Strom et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12900644/)
189. [Szuhany and Simon (2022)](https://pubmed.ncbi.nlm.nih.gov/36573969/)
190. [Terlizzi and Villarroel (2020)](https://www.cdc.gov/nchs/products/databriefs/db378.htm)
191. [Terlizzi and Zablotsky (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11616099/)
192. [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)
193. [Tucker et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29935451/)
194. [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)
195. [Vistaril prescribing information (2014)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf)
196. [Vizeli et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8149637/)
197. [Xanax prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf)
198. [Yang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8157816/)
199. [Yonkers et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8833684/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
